| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-109-8-619 |
| P698 | PubMed publication ID | 3421575 |
| P2093 | author name string | Chambers HF | |
| Miller RT | |||
| Newman MD | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| P304 | page(s) | 619-624 | |
| P577 | publication date | 1988-10-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. | |
| P478 | volume | 109 |
| Q77340008 | -Curative and preventive antibiotic therapy in infective endocarditis- |
| Q41646436 | A closer look at vancomycin, teicoplanin, and antimicrobial resistance |
| Q72370265 | Abbreviated therapy for right-sided Staphylococcus aureus endocarditis in injecting drug users: the time has come? |
| Q41999444 | Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations |
| Q36689490 | Anti-infective research and development--problems, challenges, and solutions |
| Q37333194 | Are glycopeptides still appropriate and convenient for empiric use? |
| Q35607636 | Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. |
| Q36753343 | Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci |
| Q35820407 | Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus |
| Q37733561 | Ceftaroline for complicated skin and skin-structure infections. |
| Q58380901 | Changing Populations: The Elderly, Injection Drug Users, Health-Care Associated Endocarditis and Immunocompromised Patients |
| Q37403783 | Clinical Reasoning of Infectious Diseases Physicians Behind the Use or Nonuse of Transesophageal Echocardiography in Staphylococcus aureus Bacteremia |
| Q41148527 | Clinical approach to infective endocarditis |
| Q74823204 | Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance |
| Q37849391 | Clinical management of Staphylococcus aureus bacteraemia |
| Q37153976 | Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy |
| Q35030135 | Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis |
| Q38008408 | Complicated community-acquired Staphylococcus endocarditis and multiple lung abscesses: case report and review of literature. |
| Q34715681 | Current best practices and guidelines. Assessment and management of complications in infective endocarditis |
| Q73697479 | Current best practices and guidelines. Assessment and management of complications in infective endocarditis |
| Q44439560 | Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial |
| Q39558119 | Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains. |
| Q37663120 | Endocarditis in the emergency department |
| Q36776221 | Endovascular Infections Arising from Right-Sided Heart Structures |
| Q42445383 | Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations |
| Q36752580 | Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon |
| Q33723213 | Gram-positive endocarditis |
| Q74154866 | Growth medium effect on the antifungal activity of LY 303366 |
| Q53879693 | Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. |
| Q35898084 | Hepatitis update. The delta virus |
| Q36095086 | Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus |
| Q37625071 | Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model |
| Q40950966 | Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention |
| Q54025752 | Indications for vancomycin in dialysis patients. |
| Q73236695 | Infective Endocarditis |
| Q35179332 | Infective Endocarditis in Intravenous Drug Abusers |
| Q35182561 | Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients |
| Q77575853 | Infective endocarditis and glycopeptides |
| Q34715522 | Infective endocarditis in intravenous drug abusers and HIV-1 infected patients |
| Q34950541 | Infective endocarditis in the injection drug user |
| Q77307774 | Inflammatory disorders of the heart. Pericarditis, myocarditis, and endocarditis |
| Q50791170 | Issues in the Management of Endocarditis Caused by Resistant Gram-positive Organisms. |
| Q36322109 | Management of healthcare-associated methicillin-resistant Staphylococcus aureus |
| Q37924215 | Medical complications of intravenous drug use. |
| Q30306476 | Methicillin-Resistant Staphylococcus aureus Infections |
| Q35662677 | Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). |
| Q43250858 | Mixed bacterial endocarditis in an intravenous drug misuser |
| Q33587960 | New perspectives of infections in cardiovascular disease |
| Q56798087 | Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy |
| Q40823220 | Outpatient parenteral antibiotic therapy. Management of serious infections. Part II: Amenable infections and models for delivery. Endocarditis |
| Q35123155 | Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. |
| Q35295593 | Postpartum culture negative endocarditis: a case report and review of the current guidelines |
| Q35273507 | Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin |
| Q35182550 | Progress toward a global understanding of infective endocarditis. Lessons from the International Collaboration on Endocarditis |
| Q72370279 | Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cádiz |
| Q41634913 | Recognition, management and prophylaxis of endocarditis |
| Q41148520 | Revised diagnostic criteria for infective endocarditis |
| Q35111909 | Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. |
| Q37516402 | Right-sided infective endocarditis: recent epidemiologic changes |
| Q33883648 | Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations |
| Q37636908 | Short-course therapy for bloodstream infections in immunocompetent adults |
| Q43453462 | Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. |
| Q74483951 | Short-course therapy for right-sided endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin |
| Q73697469 | Staphylococcus aureus bacteremia and endocarditis |
| Q74393437 | Staphylococcus aureus bacteremia and endocarditis |
| Q45032405 | Staphylococcus aureus endocarditis in Danish intravenous drug users: high proportion of left-sided endocarditis |
| Q34478074 | Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. |
| Q40668402 | Staphylococcus aureus: The persistent pathogen |
| Q46867744 | Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin |
| Q24675979 | Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users |
| Q73323294 | Vancomycin prescribing practices in hospitalized chronic hemodialysis patients |
| Q81146088 | [S2 Guideline for diagnosis and therapy of infectious endocarditis] |
Search more.